AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Company profile
Ticker
AZN, AZNCF
Exchange
Website
CEO
Pascal Soriot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZENECA GROUP PLC
SEC CIK
AZN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
6-K
Block Listing Interim Review
1 Jun 23
6-K
Total Voting Rights
1 Jun 23
6-K
Lynparza Approved In Us for Brcam Prostate Cancer
1 Jun 23
6-K
Imfinzi + Lynparza Prolonged PFS In Endometrial Cancer
26 May 23
25-NSE
Exchange delisting
25 May 23
6-K
Directorate Change
22 May 23
6-K
Tagrisso Plus Chemo Improved PFS In Lung Cancer
17 May 23
6-K
Director/pdmr Shareholding
9 May 23
6-K
Farxiga Extended In the Us for Heart Failure
9 May 23
6-K
Total Voting Rights
2 May 23
Latest ownership filings
SC 13G/A
Aridis Pharmaceuticals, Inc.
10 Feb 23
SC 13G/A
PIERIS PHARMACEUTICALS, INC.
10 Feb 23
SC 13G/A
BlackRock Inc.
24 Jan 23
SC 13G
BlackRock Inc.
8 Jul 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
7 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13G
Aridis Pharmaceuticals, Inc.
27 Jul 21
11-K
Annual report of employee stock purchases
29 Jun 21
SC 13G
PIERIS PHARMACEUTICALS, INC.
8 Apr 21
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
0.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 3 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 25.47 mm |
| Total shares | 1.14 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vigilant Capital Management | 772.00 | $105.00 k |
| Byrne Asset Management | 186.00 | $25.34 mm |
| Strengthening Families & Communities | 178.00 | $24.00 k |
News
AstraZeneca Earlier Announced The Discontinuation Of The Brazikumab Inflammatory Bowel Disease Development Program
1 Jun 23
AstraZeneca Announced Lynparza Plus Abiraterone Approved In The US For The Treatment Of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
1 Jun 23
Nvidia Becomes Ninth Company To Hit $1-Trillion Market Cap — Which Stock Could Be Next To Join Elusive Club?
30 May 23
BioLight Announces A Joint Cooperation Agreement With Alexion To Explore An Innovative Technology Based On Natural Tears For The Diagnosis Of Retinal Diseases
30 May 23
Argus Research Maintains Buy on AstraZeneca, Lowers Price Target to $80
26 May 23
Press releases
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
1 Jun 23
Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec's 3D Spheroid Screening Platform, KIYA-PredictTM
30 May 23
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
26 May 23
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
25 May 23
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
25 May 23